Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-27T08:07:18.131Z Has data issue: false hasContentIssue false
  • English
  • Français

Compliance and convenience: do physicians and patients see depot medication differently?

Published online by Cambridge University Press:  24 June 2014

Pierre Chue
Pierre Chue*
Affiliation:
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
*
Dr Pierre Chue, 3rd Floor, 9942-108 St., Edmonton, Alberta, Canada T5K 2J5. Tel: +1 780 428 1776; Fax: +1 780 425 9317; E-mail: pchue@ualberta.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

Physicians' attitudes to depot medication are often focused on improved compliance (adherence), and thus, short- and long-term treatment outcomes. By contrast, patients receiving such formulations tend to have a quite different viewpoint of medication. Factors such as convenience, side-effects and their beliefs about their illness play an important role in determining whether patients will adhere to their prescribed treatment regimen. The relationship between the patient and physician is of crucial importance in determining a patient's attitude to their medication; it is becoming increasingly clear that managing the illness in the long-term and avoiding relapse, while ensuring compliance, should be reframed as a collaborative process between the patient and physician.

Keywords

adherenceantipsychoticscompliancedepotneurolepticsschizophrenia
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 6 , December 2004 , pp. 314 - 318
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kampman, O, Lehtinen, K.Compliance in psychoses. Acta Psychiatr Scand 1999;100: 167–175. CrossRefGoogle ScholarPubMed
Lindström, E, Bingefors, K.Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18: 106–124. Google ScholarPubMed
Babiker, I E.Noncompliance in schizophrenia. Psychiatr Dev 1986;4: 329–337. Google Scholar
Adams, J, Scott, J.Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000;101: 119–124. CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Meise, U, Gunther, V, Kurz, M.Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;382: 11–15. Google ScholarPubMed
Bebbington, PE.The content and context of compliance. Int Clin Psychopharmacol 1995;9 (Suppl. 5):41–50. CrossRefGoogle ScholarPubMed
Oehl, M, Hummer, M, Fleischhacker, WW.Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000;102: 83–86. CrossRefGoogle Scholar
Blackwell, B.Treatment adherence. Br J Psychiatry 1976;129: 513–531. CrossRefGoogle ScholarPubMed
Wright, EC.Non-compliance – or how many aunts has Matilda? Lancet 1993;342: 909–913. CrossRefGoogle ScholarPubMed
Corrigan, PW, Liberman, RP, Engel, JD.From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41: 1203–1211. Google ScholarPubMed
Duncan, JC, Rogers, R.Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998;43: 1133–1137. CrossRefGoogle ScholarPubMed
Curson, DA, Barnes, TR, Bamber, RW, Platt, SD, Hirsch, SR, Duffy, JC.Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146: 469–474. CrossRefGoogle ScholarPubMed
Young, J, Zonana, H, Shepler, L.Medication compliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14: 105–122. Google ScholarPubMed
Green, Jh.Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988;39: 963–966. Google ScholarPubMed
Weiden, P, Glazer, W.Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q 1997;68: 377–392. CrossRefGoogle ScholarPubMed
Olfson, M, Mechanic, D, Hansell, S, Boyer, CA, Walkup, J, Weiden, PJ.Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51: 216–222. CrossRefGoogle ScholarPubMed
Gilbert, PL, Harris, MJ, McAdams, LA, Jeste, DV.Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52: 173–188. CrossRefGoogle ScholarPubMed
Ayuso-Gutierrez, JL, Rio Vega, JM.Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28: 199–206. CrossRefGoogle ScholarPubMed
Gitlin, M, Nuechterlein, K, Subotnik, KLet al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158: 1835–1842. CrossRefGoogle ScholarPubMed
Gerlach, J.Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995;9 (Suppl. 5):17–20. CrossRefGoogle ScholarPubMed
Cramer, JA, Rosenheck, R.Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196–201. CrossRefGoogle ScholarPubMed
Hogan, TP, Awad, AG, Eastwood, R.A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13: 177–183. CrossRefGoogle ScholarPubMed
Naber, D.A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10 (Suppl. 3):133–138. Google ScholarPubMed
Thompson, K, Kulkarni, J, Sergejew, AA.Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42: 241–247. CrossRefGoogle ScholarPubMed
Remington, GJ, Adams, ME.Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40: S5–S11. Google ScholarPubMed
Davis, JM, Matalon, L, Watanabe, MD, Blake, L, Metalon, L.Depot antipsychotic drugs. Place in therapy. Drugs 1994;47: 741–773. CrossRefGoogle ScholarPubMed
Valenstein, M, Copeland, LA, Owen, R, Blow, FC, Visnic, S.Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62: 545–551. CrossRefGoogle Scholar
Keith, SJ, Kane, JM.Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64: 1308–1315. CrossRefGoogle Scholar
Smith, CM, Barzman, D, Pristach, CA.Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 1997;37: 147–154. CrossRefGoogle ScholarPubMed
WHO. Report of the International Pilot Study of Schizophrenia, Vol. 1. Geneva: World Health Organization, 1973. Google Scholar
Fleischhacker, WW, Oehl, MA, Hummer, M.Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64 (Suppl. 16):10–13. Google ScholarPubMed
Droulout, T, Liraud, F, Verdoux, H.[Relationships between insight and medication adherence in subjects with psychosis]. Encephale 2003;29: 430–437. Google Scholar
Mutsatsa, SH, Joyce, EM, Hutton, SBet al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108: 439–446. CrossRefGoogle ScholarPubMed
Bartko, G, Herczeg, I, Zador, G.Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988;77: 74–76. CrossRefGoogle ScholarPubMed
Weiden, PJ, Shaw, E, Mann, JJ.Causes of neuroleptic noncompliance. Psychiatr Ann 1986;16: 571–575. CrossRefGoogle Scholar
Tattan, TM, Creed, FH.Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001;27: 149–155. CrossRefGoogle ScholarPubMed
Hofer, A, Kemmler, G, Eder, U, Honeder, M, Hummer, M, Fleischhacker, WW.Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002;63: 49–53. CrossRefGoogle ScholarPubMed
Myers, ED.Age, persistence and improvement in an open out-patient group. Br J Psychiatry 1975;127: 157–159. CrossRefGoogle Scholar
Owen, RR, Fischer, EP, Booth, BM, Cuffel, BJ.Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47: 853–858. Google ScholarPubMed
Weiden, P. From compliance to alliance in schizophrenia. Presented at the 50th Annual Meeting of the Canadian Psychiatric Association, Victoria, BC, Canada, 2000.Google Scholar
Bond, WS, Hussar, DA.Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991;48: 1978–1988. Google ScholarPubMed
Marder, SR.Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998;59 (Suppl. 3):21–25. Google ScholarPubMed
Rosenheck, R, Chang, S, Choe, Yet al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61: 382–386. CrossRefGoogle ScholarPubMed
Kelly, GR, Scott, JE, Mamon, J.Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990;28: 1181–1197. CrossRefGoogle ScholarPubMed
Zhang, M, Wang, M, Li, J, Phillips, MR.Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 1994;24: 96–102. Google Scholar
Angermeyer, MC, Matschinger, H.Lay beliefs about schizophrenic disorder: the results of a population survey in Germany. Acta Psychiatr Scand Suppl 1994;382: 39–45. CrossRefGoogle ScholarPubMed
Heyscue, BE, Levin, GM, Merrick, JP.Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998;49: 1232–1234. CrossRefGoogle ScholarPubMed
Buchanan, A.A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22: 787–797. CrossRefGoogle ScholarPubMed
Baldessarini, RJ.Enhancing treatment with psychotropic medicines. Bull Menninger Clin 1994;58: 224–241. Google ScholarPubMed
Awad, AG, Hogan, TP.Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 1994;380: 27–32. CrossRefGoogle ScholarPubMed
Pereira, S, Pinto, R.A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95: 464–468. CrossRefGoogle ScholarPubMed
Adams, SG Jr, Howe, JT.Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181: 558–560. CrossRefGoogle Scholar
Walburn, J, Gray, R, Gournay, K, Quraishi, S, David, AS.Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179: 300–307. CrossRefGoogle ScholarPubMed